Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sirna Therapeutics Inc -- Ignore unavailable to you. Want to Upgrade?

To: Scott Ozer who wrote (257)	9/7/1999 11:46:00 PM
From: bob zagorin	Read Replies (1) \| Respond to of 562

Subj: Corporate Profile for Ribozyme Pharmaceuticals Inc.,... Date: 9/3/99 7:16:44 AM Pacific Daylight Time Corporate Profile for Ribozyme Pharmaceuticals Inc., dated Sept. 3, 1999 --(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0- Published Date: Sept. 3, 1999 Company Name: Ribozyme Pharmaceuticals Inc. Address: 2950 Wilderness Place Boulder, Colo. 80301 Main Telephone Number: 303/449-6500 Internet Home Page Address (URL) www.rpi.com Chief Executive Officer: Ralph E. Christoffersen, Ph.D. Chief Financial Officer: Lawrence E. Bullock Investor Relations Contact: Alene A. Holzman Business number: 303/546-8111 E-mail address: holzmaaa@rpi.com Public Relations Contact: Freeman McCue Business number: 714/557-3663 E-mail address: prarus@aol.com Industry: Biotechnology/Pharmaceuticals Trading Symbol/ Exchange: NASDAQ/RZYM Market Makers: Hambrecht & Quist Company description: Ribozyme Pharmaceuticals Inc. (RPI) is developing a new class of drugs based on "ribozymes," a form of ribonucleic acid which has the ability to inhibit protein production. RPI is collaborating with Chiron Corp. for commercialization of ANGIOZYME, a drug for the treatment of solid-tumor cancers, such as breast, prostate, colon, and rectum. This drug, which recently completed successful human clinical trials for Phase Ia and Ib, has large market potential: Some 750,000 new cancer cases are discovered each year, and some 200,000 persons die each year from these cancers in the U.S. alone. RPI is collaborating with Eli Lilly and Company to commercialize HEPTAZYME, a drug treatment for Hepatitis C, the most common blood-borne infection in the U.S., infecting some 50,000 Americans each year. Existing therapiesare ineffective in about 50% of cases and have severe side effects. In addition, RPI has other drugs in the pipeline,with 104 patents issued and another 100 pending. The company's business strategy includes: -- aggressively developing Angiozyme & Heptazyme -- identify and develop new product candidates to exploit the broad potential of ribozymes -- partner with others to develop products -- license technology in areas RPI will not pursue Recent stock price: $5.25; Market Cap: $58 million CONTACT: Ribozyme Pharmaceuticals Inc.